The rise in popularity of anti-obesity medications (AOMs), such as popular brand names Ozempic and Wegovy could see a shift ...

Hemak, president and CEO of the Wright Centers for Community Health and Graduate Medical Education, was named one of the 100 most powerful and influential female leaders in ...

GLP-1 medications linked to a lower risk of dementia and addiction but higher risk of kidney, pancreatic, and ...

The media queen also confessed that she was reluctant to take a GLP-1 drug because she felt it was “the easy way out.” That ...

Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to treat ...

GLP-1 drugs have also demonstrated potential in reducing risks of several substance use disorders such as those involving alcohol, tobacco, cannabis, opioids and stimulants. This may be due to the ...

A report from The Lancet Diabetes & Endocrinology Commission has proposed new criteria for defining and diagnosing obesity, ...

The weight loss market is evolving at an unprecedented rate with the advancements in anti-obesity medications, and 2025 will ...

Lots of people are on cheaper compounded weight-loss drugs that mimic brands like Ozempic, Wegovy, and Zepbound. They're ...

California gastroenterologist Dr. Saurabh Sethi has called out three popular drinks that increase the risk of Alzheimer’s.

Leading health experts challenge traditional BMI measurements and introduce a comprehensive new approach to diagnosing obesity, potentially affecting millions.

As demand for weight-loss injections sold under brand names such as Ozempic and Wegovy continues to soar, a study has ...